Introduction {#Sec1}
============

Melanoma is the third most common underlying diagnosis in patients with cerebral metastases, after lung and breast cancer \[[@CR1], [@CR2]\]. Indeed, clinically apparent brain metastases are observed in 18--46 % of patients with stage 4 melanoma \[[@CR3]\]. Moreover, in our experience, brain metastases are often the first and only site of recurrence in responsive and long-surviving patients with metastatic melanoma.

Few treatment options are available for patients with melanoma brain metastases. Current management typically involves surgery or radiotherapy, with treatment decisions influenced by the number and size of lesions, as well as the extent of extracerebral metastatic disease \[[@CR4]\]. A single, or few, accessible lesions might be treatable by surgical excision or stereotactic radiosurgery, with whole brain radiotherapy also offered as a means of providing palliative symptom relief. For patients who refuse radiotherapy, or those who are not eligible for other treatments because they have symptomatic brain metastases or a poor performance status (PS), corticosteroids or other supportive measures may be considered \[[@CR1], [@CR4], [@CR5]\]. Chemotherapies can also be used to control the symptoms of brain metastases, but have limited efficacy \[[@CR1], [@CR2]\]. This may reflect the fact that most agents poorly penetrate the blood brain barrier (BBB) and do not cross into the central nervous system (CNS) in adequate quantities to have an antitumor effect \[[@CR2], [@CR6]\]. However, there is much debate about the role of the BBB in patients with brain metastases. While some evidence suggests that it is disrupted in patients with established brain metastases, other studies have shown it can be preserved \[[@CR7], [@CR8]\].

New treatments are therefore required to improve the prognosis and quality of life of patients with melanoma brain metastases. As patients with brain metastases have been historically excluded from clinical trials due to their poor prognosis, or are often under-represented, limited data are available to support the use of novel treatments in this patient population. There is evidence to suggest that inhibitors of mutated BRAF^V600^ kinase may be an effective treatment option. For example, treatment with vemurafenib, indicated for patients with advanced BRAF^V600^ mutation-positive melanoma, resulted in a disease control rate (DCR) of 67 % in 24 pretreated patients with symptomatic brain metastases \[[@CR9]\]. Intracranial objective response rates of 35 and 15 % were reported in pretreated patients with brain metastases and BRAF^V600E^ and BRAF^V600K^ mutation-positive melanoma, respectively, following treatment with the BRAF inhibitor dabrafenib \[[@CR10]\].

The immunotherapeutic agent ipilimumab is another potential treatment for patients with melanoma brain metastases. By blocking cytotoxic T-lymphocyte associated antigen-4 (CTLA-4), a negative regulator of T-cell activation, ipilimumab potentiates prolonged T-cell activation, proliferation and infiltration into tumors, leading to tumor cell death \[[@CR11]\]. Ipilimumab 3 mg/kg is registered in the European Union for the treatment of adult patients with advanced (unresectable or metastastic) melanoma \[[@CR12]\]. In randomized, controlled phase 3 trials, ipilimumab significantly improved overall survival (OS) in both pretreated and treatment-naïve patients with metastatic melanoma \[[@CR13], [@CR14]\]. Many patients treated with ipilimumab in phase 2 and 3 trials, at different doses and combinations, have achieved long-term survival, with 5-year survival rates ranging from 13 to 36 % \[[@CR15], [@CR16]\]. Ipilimumab is generally well tolerated \[[@CR13]\], with most adverse events (AEs) manageable using guidelines that have been established throughout the ipilimumab clinical development program \[[@CR12], [@CR17], [@CR18]\].

Clinical trial data suggest that ipilimumab, at a dose of 3 or 10 mg/kg, has activity in patients with brain metastases \[[@CR13], [@CR19]--[@CR23]\]. In a phase 2 prospective trial of patients who were either neurologically asymptomatic (*n* = 51) or symptomatic and on a stable dose of corticosteroids (*n* = 21), the DCR with ipilimumab 10 mg/kg was 25 and 10 %, respectively. Median OS was 7 months for asymptomatic patients, with 1 and 2-year survival rates of 31 and 26 %. Equivalent results for patients with symptomatic brain metastases were 3.4 months, with survival rates of 19 and 10 % \[[@CR19]\]. In another phase 2 trial investigating the efficacy of ipilimumab 10 mg/kg plus fotemustine, a chemotherapy known to cross the BBB, 10 out of 20 patients with asymptomatic brain metastases at baseline achieved disease control, including five patients with brain metastases that became undetectable by scan \[[@CR20]\]. Based on the results of this trial, a phase 3 trial exploring fotemustine with or without ipilimumab in patients with advanced melanoma and brain metastases is underway.

The activity of ipilimumab in patients with brain metastases is explained by its mechanism of action, as ipilimumab activates the immune system rather than acting on the tumor directly \[[@CR14]\]. Current understanding is that T-cells activated by ipilimumab can migrate across the BBB unhindered to mount an intracerebral antitumor immune response \[[@CR24], [@CR25]\].

Here, findings are reported from Italian centers participating in an Expanded Access Program (EAP) which included a subset of patients with brain metastases \[[@CR26]\]. The EAP provided an opportunity to treat patients with ipilimumab at its licensed dose of 3 mg/kg outside of a clinical trial setting.

Patients and methods {#Sec2}
====================

Patients {#Sec3}
--------

This was a retrospective analysis of patients whose physician requested compassionate use of ipilimumab through the EAP. Patients with a diagnosis of unresectable stage 3/4 cutaneous, ocular or mucosal melanoma were eligible for inclusion if they were aged 16 or over, had an Eastern Cooperative Oncology Group (ECOG) PS of 0 to 2, had previously failed or were intolerant to at least one systemic therapy for metastatic melanoma and were not eligible for a clinical trial of ipilimumab. Patients with asymptomatic brain metastases at baseline were also eligible for inclusion. Previous systemic therapy should have been completed 28 days prior to treatment with ipilimumab. However, palliative radiation therapy outside of the brain, therapeutic radiation to the brain, or systemic steroids for the management of brain metastases could be administered in the 28 days prior to treatment, at the lowest fixed dose possible.

Study design and treatment plan {#Sec4}
-------------------------------

Patients were treated with ipilimumab at a dose of 3 mg/kg, administered once every 3 weeks for four treatments. Ipilimumab was administered via a 90-minute intravenous infusion on weeks 1, 4, 7 and 10. In the absence of dose-limiting toxicities, it was recommended that patients receive all four doses of ipilimumab, providing their PS remained stable. Dose omission or discontinuation of treatment was recommended when necessary, based on specific safety criteria, but dose reductions or modifications of ipilimumab were not allowed. Patients who progressed after either ≥3 months' stable disease (SD) or an initial objective response \[complete response (CR) or partial response (PR)\] were eligible for retreatment with ipilimumab at 3 mg/kg every 3 weeks for four doses.

Assessments {#Sec5}
-----------

Tumor assessments were performed at baseline and after completion of treatment (week 12) according to immune-related (ir) response criteria: irCR, complete disappearance of all lesions whether measurable or not, and no new lesions; irPR, decrease in tumor burden ≥50 % relative to baseline; irSD, not meeting criteria for irCR or irPR, in absence of ir progressive disease (irPD); irPD, increase in tumor burden ≥25 % relative to nadir (the minimum recorded tumor burden) \[[@CR27]\]. irCR, irPR and irPD require confirmation by a repeat, consecutive assessment at least 4 weeks from the date of first documentation \[[@CR27]\]. Clinical benefit was defined as irCR, irPR or irSD for at least 3 months.

All patients who received ipilimumab in the EAP were monitored and assessed for AEs, including irAEs, which were graded using the Common Terminology Criteria for Adverse Events, version 3.0. AEs were managed using protocol-specific guidelines.

Statistical analysis {#Sec6}
--------------------

Patient and disease characteristics were analyzed using descriptive statistics, and expressed as relative frequencies (percentages) for discrete variables and median for continuous variables. Progression-free survival (PFS) and OS were estimated using Kaplan--Meier analysis and expressed as median values with corresponding two-sided 95 % confidence intervals (CIs).

A univariate analysis and Cox proportional hazards regression model were used to analyse the relationship between prognostic factors and OS.

Results {#Sec7}
=======

Patients and treatment {#Sec8}
----------------------

Of 855 patients with advanced melanoma treated in the EAP at participating Italian centers, 146 had asymptomatic brain metastases at baseline. Baseline patient characteristics are provided in Table [1](#Tab1){ref-type="table"}. As per protocol, all patients had received systemic therapy before treatment with ipilimumab, including 20 patients (14 %) who had received three or more prior therapies. Twenty-two patients (15 %) had been treated with a BRAF inhibitor, all of whom had brain metastases at the time of BRAF inhibition. Of these 22 patients, 3 (18 %) had a CR to BRAF-inhibitor treatment, 6 (35 %) had a PR and 5 (29 %) had SD, for a DCR of 82 %. Among 26 patients (18 %) who were being treated with steroids at enrollment, 13 (9 %) continued steroid treatment during ipilimumab therapy. Six patients (4 %) had received prior radiotherapy for brain metastasis.Table 1Baseline patient characteristicsCharacteristic*n* = 146Median age, years (range)54 (17--78)Sex (female/male) \[*n* (%)\]70 (48)/76 (52)ECOG PS \[*n* (%)\] 085 (58) 157 (39) 24 (3)Time from diagnosis, months (range)39 (4--260)Patients with liver metastases \[*n* (%)\]55 (38)Patients with ocular melanoma \[*n* (%)\]1 (1)Patients with mucosal melanoma \[*n* (%)\]5 (3)Elevated LDH (\>480 IU/L) \[*n* (%)\]^a^52 (45)Number of previous therapies 179 (54) 247 (32) ≥320 (14)Previous therapy \[*n* (%)\] Dacarbazine52 (36) Fotemustine59 (40) Temozolomide79 (54) Platinum-based chemotherapy54 (37) Interferon20 (14) BRAF inhibitor22 (15) Received prior radiotherapy for brain metastasis \[*n* (%)\]6 (4)*ECOG* Eastern Cooperative Oncology Group, *LDH* lactate dehydrogenase, *PS* performance status^a^Out of 115 patients evaluated for LDH levels

Among the 146 treated patients, 74 (51 %) received all four doses of ipilimumab, 28 (19 %) received three doses, 18 (12 %) received two doses and 26 (18 %) received one dose. One patient (1 %) with an irPR and 2 (1 %) with irSD as their best response to induction therapy were retreated with ipilimumab at a dose of 3 mg/kg upon disease progression; neither regained disease control. The most common reasons for not completing treatment were early progression (*n* = 27), death (*n* = 15), study drug toxicity (*n* = 7) or unrelated AEs (*n* = 3).

Efficacy {#Sec9}
--------

Of the 146 patients, 145 were evaluable for response (1 patient was lost to follow-up). Four patients (3 %) achieved an irCR and 13 (9 %) an irPR, for a global immune-related best overall response rate of 11 % (Table [2](#Tab2){ref-type="table"}). Median time to onset of response was 3.4 months (range 3.0--9.7 months) for patients with an irCR, and 3.0 months (range 2.3--6.2 months) for patients with an irPR. Twenty-two (15 %) patients achieved irSD, giving a global irDCR of 27 %. The median duration of objective response (irCR or irPR) was 9.7 months (range 4.0--17.0 months), while median duration of irSD was 9.4 months (range 2.9--29.3 months). Of the 26 patients receiving steroid therapy at baseline, 2 (8 %) achieved an irPR and 2 (8 %) achieved irSD, for a global irDCR of 15 %. Of the remaining 119 patients, 4 (3 %) achieved an irCR, 11 (9 %) an irPR and 20 (16 %) irSD, for a global irDCR of 29 %.Table 2Tumor responseResponse according to irRCPatients \[*n* (%)\]irCR4 (3)irPR13 (9)irSD22 (15)Immune-related progressive disease106 (73)Immune-related best overall response rate17 (12)irDCR39 (27)*irCR* immune-related complete response, *irDCR* immune-related disease control rate, *irPR* immune-related partial response, *irRC* immune-related response criteria, *irSD* immune-related stable disease

With a median follow-up of 20 months (range 1 to 29+ months), estimated using Kaplan--Meier reverse methodology, median OS was 4.3 months (95 % CI 3.4--5.2) (Fig. [1](#Fig1){ref-type="fig"}). The 1-year OS rate was 20 % (95 % CI 13--26). Median PFS was 3.1 months (95 % CI 2.7--3.5), and the 1-year PFS rate was 17 % (95 % CI 10--23) (Fig. [1](#Fig1){ref-type="fig"}). Median OS among the six patients who had received prior radiotherapy for brain metastases was 5.5 months (range 2.2--6.7 months); however the number of patients was too small to perform any statistical analyses. Median OS among 20 patients previously receiving interferon therapy was 4.1 months (similar to that of the overall population of patients with brain metastases).Fig. 1Kaplan-Meier curves of OS and PFS in patients with metastatic melanoma and brain metastases. *CI* confidence interval, *OS* overall survival

Univariate analysis showed that younger age (age \<60 years; median OS: 3.7 months), ECOG PS of 2 (median OS: 3.2 months), presence of liver metastases (median OS: 3.7 months), LDH \> 480 IU/L (median OS: 3.4 months), and steroid use at baseline (median OS: 2.9 months) were significantly associated with poorer survival (Table [3](#Tab3){ref-type="table"}). After using a Cox proportional hazards model to adjust for prognostic variables, use of steroids, age and ECOG PS were significantly associated with OS.Table 3Univariate analysis of survival by baseline characteristicCharacteristic at baselineMedian OS (months)*p*Age, years(*n* ) \<60 (91)3.70.06 ≥60 (55)5.5ECOG PS (n) 0 (85)6.0\< 0.0001 1--2 (61)3.2Presence of liver metastases (*n*) Yes (55)3.70.06 No (91)4.5LDH (n) \>480 IU/L (52)3.40.03 ≤480 IU/L (63)6.2Previous use of BRAF inhibitor (*n*) Yes (22)2.50.05 No (124)5.0Steroid use (*n*) Yes (26)2.90.005 No (120)4.9*ECOG* Eastern Cooperative Oncology Group, *LDH* lactate dehydrogenase, *OS* overall survival, *PS* performance status

Safety and tolerability {#Sec10}
-----------------------

58 patients (40 %) with asymptomatic brain metastases reported an AE of any grade. These were considered treatment-related in 42 patients (29 %) (Table [4](#Tab4){ref-type="table"}). Grade III/IV AEs were reported in 15 patients (10 %) and were considered treatment-related in nine patients (6 %). The most common grade III/IV AEs were liver dysfunction, which occurred in four patients (3 %) and diarrhea, which occurred in two patients (6 %). The patients with liver dysfunction did not have liver metastases. AEs were generally reversible with treatment as per protocol-specific guidelines, and the median time to resolution of treatment-related AEs was 1.6 weeks (range 0.1--3.4). CNS events such as hemorrhage, headache and seizure were reported in ten patients (6.9 %), and were grade III/IV in five patients (3.4 %). Grade III headache and grade III confusion were each reported in 1 patient, and were considered to be possibly related to treatment (Table [4](#Tab4){ref-type="table"}).Table 4Treatment-related AEsTreatment-related AEPatients \[*n* (%)\]Any gradeGrade 3/4Total42 (29)9 (6)Diarrhea14 (10)2 (1)Nausea7 (5)1 (1)Vomiting5 (3)1 (1)Asthenia10 (7)1 (1)Pruritus4 (3)0Rash4 (3)0Liver toxicity4 (3)4 (3)Fever3 (2)0Headache1 (1)1 (1)Confusion1 (1)1 (1)*AE* adverse event

Of the 17 patients with an irCR or irPR, three patients had grade I/II AEs that were considered related to ipilimumab treatment. None had grade III/IV treatment-related AEs.

Discussion {#Sec11}
==========

The EAP allowed the efficacy and safety of ipilimumab to be evaluated in a large cohort of patients with melanoma and brain metastases in a setting that closely reflected daily clinical practice. Median OS for patients with melanoma and asymptomatic brain metastases was 4.3 months and approximately 20 % of patients were alive at 1 year. A similar analysis of data from an EAP conducted in the United States showed that among 715 patients with melanoma brain metastases, 25 % were alive 1 year after starting treatment with ipilimumab 3 mg/kg \[[@CR28]\]. Because it can take time to build an immune response against the tumor, median OS does not necessarily reflect the potential of ipilimumab to provide durable clinical benefit. It is therefore important to consider those patients surviving beyond the median \[[@CR11], [@CR27]\]. Ipilimumab activity has been shown to persist in the absence of continued treatment, with survival curves plateauing after 2--3 years and a significant proportion of patients surviving 4--5 years after initiation of treatment \[[@CR15], [@CR16], [@CR29]\]. Consequently, it is possible that ipilimumab may provide long-term survival in a significant proportion of patients with brain metastases, despite the modest median OS reported in this EAP. This will be confirmed with longer follow-up.

The irDCR in this analysis was 27 %, which is consistent with DCRs reported in clinical trials of ipilimumab. For example, in the registrational phase 3 trial of patients with pretreated metastatic melanoma, the DCR according to modified World Health Organization criteria was 29 % for the 137 patients receiving ipilimumab 3 mg/kg as monotherapy. This included 15 patients (11 %) who had stable brain metastases at baseline \[[@CR13]\].

Of note, patients who were receiving steroid therapy at baseline in the EAP tended to have a poorer irDCR than those who were not (15 vs. 29 %), and had a significantly poorer median OS. Similar results have been reported in patients treated with ipilimumab 10 mg/kg in a phase 2 trial, as previously discussed \[[@CR19]\]. This variation in outcome may simply reflect the fact that patients requiring steroid therapy have features associated with a poorer prognosis, such as higher burden of brain disease and neurological symptoms. However, it is also possible that steroids have an independent, negative effect on ipilimumab activity. Although studies have suggested that systemic steroids do not interfere with ipilimumab efficacy when used to manage treatment-related AEs \[[@CR30], [@CR31]\], the effect of steroid use prior to treatment with ipilimumab is unclear. Indeed, in a preclinical model, glucocorticoids were shown to inhibit naïve T-cells, while not impairing the antitumor activity of activated T-cells \[[@CR32]\].

In this analysis, median OS was reduced for the 22 patients who had previously been treated with a BRAF inhibitor, and univariate analysis revealed a trend for prior BRAF use to correlate with shortened survival despite ipilimumab treatment. Interestingly, a previous analysis of patients treated sequentially with ipilimumab and a BRAF inhibitor, or vice versa, showed that patients who received ipilimumab upon disease progression with a BRAF inhibitor had significantly shorter survival \[[@CR33]\]. This may be because patients were unable to complete subsequent treatment with ipilimumab due to rapid disease progression \[[@CR33], [@CR34]\].

The use of ipilimumab in patients with brain metastases could cause neurological complications due to inflammation in the brain \[[@CR19]\]. However, the results of previous studies suggest that the presence of brain metastases has no effect on the type and frequency of AEs experienced with ipilimumab treatment \[[@CR19], [@CR20]\]. In the EAP, the percentage of treatment-related AEs of any grade was lower for patients with brain metastases than for the total population \[[@CR35]\], and AEs were generally manageable. CNS AEs were experienced by 10 patients (6.9 %), including hemorrhage, headache, and seizure, but were only considered treatment-related in two patients (1 %).

Because of its retrospective nature, this subanalysis is subject to limitations. For example, brain scans were not required for enrollment; therefore, data may not be fully representative of the EAP population. Furthermore, data on intracranial versus extracranial progression and/or response rates were not available. The results therefore require validation in prospective clinical trials. However, the data presented here, together with previously published data, suggest that ipilimumab provides durable clinical benefit and has a manageable side-effect profile in patients with advanced melanoma and brain metastases. Further prospective evaluation is warranted in this hard-to-treat patient population.
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